Shionogi : Transfers All Assets in Ezose Sciences, a US Subsideary Providing Glycan Analytical Services, to Sumitomo Bakelite Co., Ltd.
August 01, 2014 at 03:51 am EDT
Share
Shionogi Transfers All Assets in Ezose Sciences, a US Subsideary Providing
Glycan Analytical Services, to Sumitomo Bakelite Co., Ltd.
Osaka, Japan, August 1, 2014 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it has entered into an agreement with Sumitomo Bakelite Co., Ltd. (Head Office: Tokyo; President: Shigeru Hayashi; hereafter "Sumitomo Bakelite") to transfer all assets in its wholly-own subsideary, Ezose Sciences, Inc. (hereafter "Ezose"), which is providing glycan analytical services in the US, to Sumitomo Bakelite.
In April 2014, Shionogi launched its New Medium-Term Business Plan toward the year 2020 "Shionogi Growth Strategy 2020 (SGS2020)" with the vision "Grow as a drug discovery-based pharmaceutical company". Based on the vision expressed in SGS2020, Shionogi is targeting two kinds of growth; first, "top-line growth" though increased focus and concentration of sales effort in the most productive areas, and through the development and launch of innovative medicines in its chosen therapeutic areas, and secondly, "bottom-line growth" through continuous improvement of its business operations.
Ezose started its business in 2009, with novel serum glycan analytical technologies developed by Hokkaido University coupled with novel glycoblotting materials manufactured by Sumitomo Bakelite. Since then Ezose has developed an extensive base of knowledge and capabilities relating to the discovery of novel biomarkers and glycan analytical services, which Ezose has applied on behalf of numerous pharmaceutical companies and research institutions.
Following this transaction, Shionogi is even more tightly focused on its core priorities and thereby its further growth as a drug discovery-based pharmaceutical company. The value of glycan analytical business developed by Ezose will be maximized under the Sumitomo Bakelite group which has a lineup of glycan-related products as one of its business focus areas.
[Overview of Ezose Sciences Inc.]
1.
Company Name:
Ezose Sciences, Inc.
2.
Location:
25 Riverside Drive, Pine Brook, NJ 07058, USA
3.
Representative:
Ryuichi Kiyama, Ph.D. (Chairman & CEO)
4.
Business Description:
Glycan analytical services for bioprocessing and biomarker
discovery
5.
Capital:
15 million dollars
6.
Date of Establishment:
March 3, 2009
7.
Capital provider (%):
Shionogi & Co., Ltd. (100%)
1
[Overview of Sumitomo Bakelite Co., Ltd.]
1.
Company Name:
Sumitomo Bakelite Co., Ltd.
2.
Location:
5-8 Higashi-Shinagawa 2-chome, Shinagawa-ku,
Tokyo 140-0002
3.
Representative:
Shigeru Hayashi (President)
4.
Business Description:
Production and sales of semiconductor materials,
high performance plastics and quality of life products
5.
Capital:
37,143 million yen (as of March 31, 2014)
6.
Date of Establishment:
January, 1932
7.
Major shareholder:
(percentage of ownership)
Sumitomo Chemical Co., Ltd. (19.98%, as of March 31, 2014)
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For further information, contact: Corporate Communications Department Shionogi & Co., Ltd.
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products:
- prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.;
- OTC products: analgesic products, vitamins and tonics, etc.;
- diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
SHIONOGI & CO., LTD. 
